IP Library › Granted Patent US 12,728,158
Granted Patent B2
US 12,728,158 · App. 17/617,690 · Granted Sep 8, 2026

Combination of markers for predicting the response to Vx-001

Inventors: Kostantinos (Kostas) Kosmatopoulos (Paris, FR); Jeanne Menez-Jamet (Montrouge, FR)
Assignee: KRIPTIC PHARMACEUTICALS LIMITED
A61K39/001157A61P35/00G01N33/50A61K2039/54A61K2039/572A61K2039/70G01N2333/904G01N2333/9108G01N2333/91085G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,728,158
App. No.
17/617,690
Granted
Sep 8, 2026
Kind
B2
Abstract

The invention relates to the use of an anti-tumour vaccine composed of two peptides of nine amino acids—native cryptic TERT572 (RLFFYRKSV, SEQ ID No. 1), expressed by tumour cells, and the optimised variant thereof TERT572Y (YLFFYRKSV, SEQ ID No. 2), for the treatment of a tumour expressing telomerase reverse transcriptase (TERT), in an HLA-A*0201 patient with a normal gamma glutamine transferase (gGT) level and/or a normal lactate dehydrogenase (LDH) level.

Claims (10)

1 . A method of prolonging survival and/or time to failure (TFF) of a HLA-A*0201-positive patient having a lung tumor expressing Telomerase Reverse Transcriptase (TERT) comprising a step of selecting a HLA-A*0201-positive patient having a lung tumor expressing Telomerase Reverse Transcriptase (TERT) and who has a normal level of gamma Glutamine Transferase (gGT) and/or a normal level of lactate dehydrogenase (LDH) and a step of administering a Vx-001 anti-cancer vaccine comprising a peptide of SEQ ID NO: 2 and a peptide of SEQ ID NO: 1 to the selected patient, wherein the administering of the Vx-001 anti-cancer vaccine to the selected patient prolongs survival and/or TFF of the patient as compared to placebo.

2 . The method of claim 1 , wherein the patient has a normal level of gGT and a normal level of LDH.

3 . The method of claim 1 , wherein the patient suffers from a non-small cell lung cancer.

4 . The method of claim 1 , wherein the Vx-001 anti-cancer vaccine is administered to the patient further to a first-line chemotherapy.

5 . The method of claim 1 , wherein the patient is a male patient.

6 . The method of claim 1 , wherein the patient has a non-squamous tumor.

7 . The method of claim 1 , wherein the patient is less than 65 years old.

8 . The method of claim 1 , wherein the patient has cancer which is no longer progressing after a first-line chemotherapy.

9 . The method of claim 1 , wherein the patient has an Eastern Cooperative Oncology Group functional index (ECOG) score of 0.

10 . The method of claim 1 , wherein the patient has a tumor which does not express the PD-L1 molecule and/or is not infiltrated with lymphocytes.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2024
From: VAXON BIOTECH
To: KRIPTIC PHARMACEUTICALS LIMITED
Reel/Frame 067492/0552 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2023
From: VAXON BIOTECH
To: KRIPTIC PHARMACEUTICALS LIMITED
Reel/Frame 063449/0437 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2021
From: KOSMATOPOULOS, KOSTANTINOS (KOSTAS); MENEZ-JAMET, JEANNE
To: VAXON BIOTECH
Reel/Frame 058355/0078 →
Priority Claims (1)
FR 1906208 · Jun 11, 2019 · national
Continuity (1)
Related Publication 20220249642A1 · Aug 11, 2022
References Cited (18)
WO WO2006120038A2 · 2006 [cited by examiner]
Kailashiya C. et al. Telomerase based anticancer immunotherapy and vaccines approaches. Vaccine. 2017 (Year: 2017). [cited by examiner]
Aykan NF. et al. Objective response rate assessment in oncology: Current situation and future expectations. World J Clin Oncol. 2020 (Year: 2020). [cited by examiner]
Bozkaya, Y. et al. Prognostic significance of gamma-glutamyl transferase in patients with metastatic non-small cell lung cancer. Expert Review of Molecular Diagnostics. 2019 (Year: 2019). [cited by examiner]
Georgoulias, V. et al. A Multicenter Randomized Phase IIb Efficacy Study of Vx-001, a Peptide-Based Cancer Vaccine as Maintenance Treatment in Advanced Non-Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynami… [cited by examiner]
Kotsakis A. et al. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. Lung Cancer. 2014 (Year: 2014). [cited by examiner]
Lin, G. et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. Oncotarget. 2017 (Year: 2017). [cited by examiner]
Kotsakis et al., “Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study,” Annal… [cited by applicant]
Georgoulias et al., “A Multicenter Randomized Phase IIb Efficacy Study of Vx-001, a Peptide-Based Cancer Vaccine as Maintenance Treatment in Advanced Non-Small-Cell Lung Cancer: Treatment Rationale and Protocol Dynamics… [cited by applicant]
Gridelli et al., “Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical … [cited by applicant]
Menez-Jamet et al., “Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines,” Annals of Translational Medicine, 4 (14): 266 (2016). [cited by applicant]
Ferrucci et al., “Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab,” Annals of Oncology, 27: 732-738 (2016). [cited by applicant]
Mezquita et al., “Association of Lung Immune Prognostic Index with Immune Checkpoint Inhibitor Outcomes in Patients with Advanced Non-Small Cell Lung Cancer,” JAMA Oncology, 4 (3): 351-357 (2018). [cited by applicant]
Tourdot et al., “A general strategy to enhance immunogenicity of low-affinity HLA-A2.1-associated peptides: implication in the identification of cryptic tumor epitopes,” European Journal of Immunology, 30 (12): 3411-342… [cited by applicant]
“Vaxon-biotech>VX-001” <<https://web.archive.org/web/20170408155422/http://vaxon-biotech.com/>page_id=122>> (2017) (retrieved Mar. 27, 2020). [cited by applicant]
“Novel Vaccine Shows Association with Survival Based on Smoking History in Patients with Advanced NSCLC,” <<https://www.targetedonc.com/conference/esmo-2017/novel-vaccine-shows-association-with-survival-based-on-smoking… [cited by applicant]
“Lung cancer: Vaxon announces results of its Vx-001 therapeutic vaccine Phase IIb trial -Andrew Lloyd & Associates,” <<https://ala.com/vaxon-announces-results-of-its-phase-iib-lung-cancer-trial-of-vx-001-a-therapeutic-v… [cited by applicant]
International Search Report issued in corresponding International Patent Application No. PCT/FR2020/050975 dated Sep. 17, 2020. [cited by applicant]